AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ORTHOCELL LTD

0.825

+0.0050.61%

Volume:226.38K

Turnover:186.81K

Market Cap:223.65M

PE:-15.82

High:0.835

Open:0.830

Low:0.820

Close:0.820

52wk High:1.700

52wk Low:0.770

Shares:271.09M

Float Shares:194.08M

Volume Ratio:0.47

T/O Rate:0.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.052

EPS(LYR):-0.038

ROE:-41.06%

ROA:-20.97%

PB:5.43

PE(LYR):-21.50

Loading ...

Overview Company News Filings

Orthocell Names UK Distributor For Nerve Repair Product, Shares Jump 3%

MT Newswires Live

Orthocell Ltd-Orthocell Appoints UK Distributor for Remplir

THOMSON REUTERS

Fed, FDIC, and OCC Issue Crucial Clarification on Blockchain-Based Securities

Vermiculus delivers VeriClear-based risk systems to OCC

Applied Materials Inc Stock Opened Down by 5.28% on Mar 3: Facts Behind the Movement

Analog Devices Inc Stock Opened Down by 3.38% on Mar 3: Key Drivers Unveiled

Arista Networks Inc Stock Opened Down by 3.07% on Mar 3: A Full Analysis

Orthocell H1 Loss Of A$5.2 Million Tests Bullish Growth Narrative

Simply Wall St.

Orthocell Eyes Fiscal 2027 Entry Into UK, European Union Markets

MT Newswires Live

BRIEF-Orthocell Posts Quarterly Revenue Of A$3.2 Million

Orthocell Finalizes Agreement With Biotechnology Company

MT Newswires Live

BRIEF-Orthocell Finalises Strategic Investment In Marine Biomedica

Orthocell Ltd - Orthocell Finalises Strategic Investment in Marine Biomedica

THOMSON REUTERS

Orthocell Ltd - Co Increased Its Equity Interest in Marine Biomedical to 11.7% for Total Investment of AU$1.05 Million

THOMSON REUTERS

BRIEF-Orthocell Posts A$3.2 Million In Revenue For Quarter Ended 31 December

Orthocell Posts 45% Revenue Growth for December 2025 Quarter

MT Newswires Live

Orthocell Ltd - Revenue a$3.2 Mln for Quarter Ended 31 December

THOMSON REUTERS

Orthocell Sells 100 Units of Nerve Repair Product in US

MT Newswires Live

Canaccord Genuity Starts Orthocell at Speculative Buy with AU$1.33 Price Target

MT Newswires Live

Orthocell Submits Application to the British Standards Institution for Approval for Commercial Distribution of Nerve Repair Product, Shares Up 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OCC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OCC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","market":"AU","secType":"STK","nameCN":"ORTHOCELL LTD","latestPrice":0.825,"timestamp":1773292320000,"preClose":0.82,"halted":0,"volume":226380,"delay":0,"changeRate":0.0060975609756097615,"nameEN":"ORTHOCELL LTD","floatShares":194076512,"shares":271090199,"eps":-0.052151,"marketStatus":"Closed","change":0.005,"latestTime":"03-12 16:12:00 AEDT","open":0.83,"high":0.835,"low":0.82,"amount":186813,"amplitude":0.018293,"askPrice":0.835,"askSize":12798,"bidPrice":0.825,"bidSize":30717,"shortable":3,"etf":0,"ttmEps":-0.052151,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1773356400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.82,"openAndCloseTimeList":[[1773270000000,1773291600000]],"volumeRatio":0.47383,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"OCC.AU","preClose":0.82,"auctionPrice":0.825,"auctionVolume":1297,"auctionTime":1773292001538,"referencePrice":0.825,"referenceTime":1773307803089,"auction":3,"marketStatus":"盘后竞价","timestamp":1773292001538}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","floatShares":194076512,"roa":"-20.97%","roe":"-41.06%","lyrEps":-0.03837,"volumeRatio":0.47383,"shares":271090199,"dividePrice":0,"high":0.835,"amplitude":0.018293,"preClose":0.82,"low":0.82,"week52Low":0.77,"pbRate":"5.43","psRate":"23.97","week52High":1.7,"institutionHeld":0,"latestPrice":0.825,"committee":0.411789,"eps":-0.052151,"divideRate":0,"volume":226380,"delay":0,"ttmEps":-0.052151,"open":0.83,"prevYearClose":1.085,"prevWeekClose":0.885,"prevMonthClose":0.95,"prevQuarterClose":1.085,"fiveDayClose":0.895,"twentyDayClose":0.94,"sixtyDayClose":1.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OCC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OCC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OCC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618645607","title":"Orthocell Names UK Distributor For Nerve Repair Product, Shares Jump 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618645607","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618645607?lang=en_us&edition=fundamental","pubTime":"2026-03-10 11:14","pubTimestamp":1773112478,"startTime":"0","endTime":"0","summary":"Orthocell  appointed medical device distribution company LEDA Orthopaedics as the exclusive in-country distributor of its nerve repair product Remplir in the UK, according to a Tuesday Australian bourse filing.Orthocell's regulatory submission process to the British Standards Institution in December 2025 sought approval to commercially distribute Remplir in the UK and Europe, and regulatory approval is expected in the third quarter.Its shares jumped 3% in recent trading on Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2618670186","title":"Orthocell Ltd-Orthocell Appoints UK Distributor for Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2618670186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618670186?lang=en_us&edition=fundamental","pubTime":"2026-03-10 06:08","pubTimestamp":1773094133,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUEC2T1MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2617868876","title":"Fed, FDIC, and OCC Issue Crucial Clarification on Blockchain-Based Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2617868876","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617868876?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:58","pubTimestamp":1772747880,"startTime":"0","endTime":"0","summary":"Before this update, banks were largely stuck in limbo. A lot of traditional institutions were hesitant to seriously experiment with tokenizing real-world assets because they were worried regulators would penalize them with heavy capital buffers.By removing that regulatory guesswork, the Fed, FDIC, and OCC just gave traditional finance a massive green light to adopt blockchain tech.That being said, the regulators made sure to point out that this isn't a free-for-all. Banks diving into tokenized assets are still on the hook for strict risk management.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/fed-fdic-and-occ-issue-crucial-clarification-on-blockchain-based-securities","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/fed-fdic-and-occ-issue-crucial-clarification-on-blockchain-based-securities","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["BK4020","SKRE","OCC.AU","US7Y.BOND","US2Y.BOND","US10Y.BOND","FAZ","OCC","BK4585","US12M.BOND","US30Y.BOND","US3Y.BOND","BIL","BK7508","BK7067","TLTW","US6M.BOND","SHV","US5Y.BOND","BK4588","TMF"],"gpt_icon":1},{"id":"2617994546","title":"Vermiculus delivers VeriClear-based risk systems to OCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2617994546","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617994546?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:10","pubTimestamp":1772709000,"startTime":"0","endTime":"0","summary":"The Options Clearing Corporation  has accepted delivery of two essential microservice-based risk systems from Vermiculus within a few months of implementation.STOCKHOLM, March 5, 2026 /PRNewswire/ -- Vermiculus, global provider of clearing, trading and CSD technology, has delivered two VeriClear-based and modular risk systems to The Options Clearing Corporation, the world's largest equity derivatives clearing organization.\"With scalable, cloud-native microservice architecture and real-time data capabilities, the new risk systems will play a central role in OCC's risk management. Our close collaboration with Vermiculus, has been key in developing our capabilities,\"says John Martino, Managing Director, Clearing Systems at OCC. \"Vermiculus' level of quality and reliable delivery are highly valued,\" adds Martino.\"OCC is one of Vermiculus' first customers, and we have worked closely with them throughout their ongoing technology transformation. This transparent and collaborative partnership ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/vermiculus-delivers-vericlear-based-risk-systems-to-occ-302705229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK4020","BK7093","OCC","CCP.AU","SEC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2616933321","title":"Applied Materials Inc Stock Opened Down by 5.28% on Mar 3: Facts Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2616933321","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616933321?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:47","pubTimestamp":1772549263,"startTime":"0","endTime":"0","summary":"• Institutional investors reduced their holdings in Applied Materials.\n• Recent insider selling may have impacted market sentiment.\n• Analyst shifts and a tender offer extension contributed to price decline.","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/stocks/261640165-market-movers-amat-20260303","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0942090050.USD","LU0158827781.USD","LU0096364046.USD","BK4147","LU1035775433.USD","LU1267930813.SGD","LU1989763005.USD","LU2023250504.SGD","LU0158827948.USD","LU0011850046.USD","LU2023250843.SGD","LU0792757196.USD","LU1046421795.USD","IE00BSNM7G36.USD","LU0889566641.SGD","AMAT","LU1868836757.USD","LU2458330243.SGD","SELX","BK4141","IE00BD6J9T35.USD","BK4567","LU2089985449.USD","LU0354030438.USD","LU1674673691.USD","LU0957808578.USD","MOBX","LU0238689110.USD","LU0348723411.USD","LU1642822529.SGD","LU0444973449.USD","LU1721428933.USD","IE0009356076.USD","OCC.AU","LU1815336760.USD","LU0096362180.USD","LU1823568750.SGD","IE00BQXX3C00.GBP","LU0661504455.SGD","OCC","LU0957791311.USD","LU0444971666.USD","LU2413666699.HKD","LU1868836914.USD","LU1917777945.USD","LU2111349929.HKD","LU2931357623.SGD","LU0553294199.USD","LU2023251221.USD"],"gpt_icon":0},{"id":"2616432169","title":"Analog Devices Inc Stock Opened Down by 3.38% on Mar 3: Key Drivers Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2616432169","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616432169?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:47","pubTimestamp":1772549262,"startTime":"0","endTime":"0","summary":"• Stock trading ex-dividend on March 3, 2026, causes price adjustment.\n• CFO appearance at conference may influence trading activity and sentiment.\n• Strong Q1 results and dividend increase contrast with valuation concerns.","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/stocks/261640164-market-movers-adi-20260303","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443978.SGD","BK7508","LU2237438978.USD","BK4020","LU2275660780.HKD","LU0109392836.USD","BK4585","LU0124384867.USD","LU1074936037.SGD","SELX","LU1670711123.USD","ROE","LU1815336760.USD","LU2298322129.HKD","LU1861214812.USD","LU1992135399.USD","LU1992135472.HKD","LU0302445910.USD","LU0312595415.SGD","LU2360107325.USD","MOBX","LU1803068979.SGD","ADI","BK4141","BK4588","LU2458330243.SGD","IE00BD6J9T35.USD","ADI.AU","LU0444971666.USD","IE00BZ199S13.USD","LU0724618433.USD","BK4561","LU0077335932.USD","OCC.AU","LU1244550494.USD","LU0957808578.USD","LU2458330169.SGD","LU1978683503.SGD","IE0009356076.USD","LU0314104364.USD","LU1670710661.SGD","LU2237443549.SGD","LU2272731782.SGD","OCC","LU1670711040.USD","BK4515","BK4605","LU1861219969.SGD","BK7067","LU1244550577.SGD"],"gpt_icon":0},{"id":"2616532165","title":"Arista Networks Inc Stock Opened Down by 3.07% on Mar 3: A Full Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2616532165","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616532165?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:47","pubTimestamp":1772549250,"startTime":"0","endTime":"0","summary":"• Arista Networks' share price declined due to profit-taking and valuation concerns.\n• Insider selling and NVIDIA's competition are impacting investor confidence.\n• Customer concentration and reduced institutional stakes add to selling pressure.","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/stocks/261640163-market-movers-anet-20260303","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348723411.USD","BK7508","BK4141","IE00BMPRXR70.SGD","LU2211815571.USD","LU2286300806.USD","BK4543","OCC","LU0109392836.USD","LU0353189680.USD","LU2458330243.SGD","IE00BMPRXN33.USD","LU0557290698.USD","ANET","BK4020","IE00BN0W2W23.USD","SELX","LU2355687059.USD","BK4585","IE00BN0W2V16.EUR","LU2023250504.SGD","LU2106854487.HKD","LU1803068979.SGD","IE00BN0W2T93.GBP","LU0198837287.USD","SG9999001424.SGD","LU0077335932.USD","MOBX","BK7067","LU0889565833.HKD","LU2087625088.SGD","LU0106261372.USD","LU0225283273.USD","LU1917777945.USD","LU2458330169.SGD","BK4554","LU0006306889.USD","IE00BMPRXQ63.HKD","IE0008368304.USD","LU2108987350.USD","OCC.AU","LU1974910355.USD","BK4539","LU2054465674.USD","BK4588","LU0353189763.USD"],"gpt_icon":0},{"id":"2614208192","title":"Orthocell H1 Loss Of A$5.2 Million Tests Bullish Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2614208192","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614208192?lang=en_us&edition=fundamental","pubTime":"2026-02-25 16:21","pubTimestamp":1772007687,"startTime":"0","endTime":"0","summary":"Orthocell H1 2026 Earnings Snapshot\nOrthocell (ASX:OCC) has released its H1 2026 results, reporting revenue of A$5.4 million and a basic EPS loss of A$0.021, alongside a net loss of A$5.2 million. The company’s revenue moved from A$3.6 million in H1 2025 to A$5.1 million in H2 2025 and A$5.4 million in H1 2026. Over the same periods, basic EPS shifted from a loss of A$0.006 in H1 2025 to A$0.031541 in H2 2025 and A$0.021 in H1 2026. For investors, the latest results keep the focus on how...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/orthocell-h1-loss-of-a52-million-tests-bullish-growth-narrat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/orthocell-h1-loss-of-a52-million-tests-bullish-growth-narrat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BLSX","BK7508","OCC.AU","BK7067","BK4112","BLSG"],"gpt_icon":0},{"id":"2608887369","title":"Orthocell Eyes Fiscal 2027 Entry Into UK, European Union Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887369","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608887369?lang=en_us&edition=fundamental","pubTime":"2026-02-02 07:51","pubTimestamp":1769989904,"startTime":"0","endTime":"0","summary":"Orthocell  said it plans to focus on completing launch planning for its fiscal 2027 entry into the UK and European Union markets, according to a Monday Australian bourse filing.Its total revenue for the first half of fiscal 2026 came in at AU$6.2 million, up from AU$4.2 million in the year-ago period.Orthocell estimated that it requires around 10,000 unit sales of its Remplir nerve repair product per annum in the US to reach cash breakeven, which is less than 1% of the addressable market, per the filing.The firm's shares rose 1% in early trading on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2604034649","title":"BRIEF-Orthocell Posts Quarterly Revenue Of A$3.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2604034649","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604034649?lang=en_us&edition=fundamental","pubTime":"2026-01-19 09:10","pubTimestamp":1768785047,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Posts Quarterly Revenue Of A$3.2 MillionJan 19 (Reuters) - Orthocell Ltd OCC.AX:QTRLY REVENUE OF A$3.2 MILLIONFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nFWN3YH1FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2603955861","title":"Orthocell Finalizes Agreement With Biotechnology Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2603955861","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603955861?lang=en_us&edition=fundamental","pubTime":"2026-01-16 10:46","pubTimestamp":1768531607,"startTime":"0","endTime":"0","summary":"Orthocell  finalized an agreement with Marine Biomedical, increasing its equity interest to 11.7% from 1.72% for a total investment of AU$1.1 million, according to a Friday filing with the Australian bourse.The company also secured global distribution rights to PearlBone, Marine Biomedical's bone regeneration technology, as well as its future bone repair products under the deal, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2603951930","title":"BRIEF-Orthocell Finalises Strategic Investment In Marine Biomedica","url":"https://stock-news.laohu8.com/highlight/detail?id=2603951930","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603951930?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:24","pubTimestamp":1768526652,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Finalises Strategic Investment In Marine BiomedicaJan 16  - Orthocell Ltd OCC.AX:ORTHOCELL FINALISES STRATEGIC INVESTMENT IN MARINE BIOMEDICACO INCREASED ITS EQUITY INTEREST IN MARINE BIOMEDICAL TO 11.7% FOR TOTAL INVESTMENT OF AU$1.05  MILLIONFurther company coverage: OCC.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nFWN3YG0RI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2603780936","title":"Orthocell Ltd - Orthocell Finalises Strategic Investment in Marine Biomedica","url":"https://stock-news.laohu8.com/highlight/detail?id=2603780936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603780936?lang=en_us&edition=fundamental","pubTime":"2026-01-16 06:03","pubTimestamp":1768514586,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0RI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2603752936","title":"Orthocell Ltd - Co Increased Its Equity Interest in Marine Biomedical to 11.7% for Total Investment of AU$1.05  Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2603752936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603752936?lang=en_us&edition=fundamental","pubTime":"2026-01-16 06:03","pubTimestamp":1768514586,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0RI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2601859763","title":"BRIEF-Orthocell Posts A$3.2 Million In Revenue For Quarter Ended 31 December","url":"https://stock-news.laohu8.com/highlight/detail?id=2601859763","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601859763?lang=en_us&edition=fundamental","pubTime":"2026-01-06 09:13","pubTimestamp":1767662035,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Posts A$3.2 Million In Revenue For Quarter Ended 31 DecemberJan 6 (Reuters) - Orthocell Ltd OCC.AX:REVENUE A$3.2 MILLION FOR QUARTER ENDED 31 DECEMBERFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y618G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2601859912","title":"Orthocell Posts 45% Revenue Growth for December 2025 Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2601859912","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601859912?lang=en_us&edition=fundamental","pubTime":"2026-01-06 09:01","pubTimestamp":1767661283,"startTime":"0","endTime":"0","summary":"Orthocell  posted revenue of AU$3.2 million for the quarter ended Dec. 31, 2025, up 45% on the previous corresponding period, according to a Tuesday filing with the Australian bourse.Revenue for the period also represents a 7% increase over the previous quarter and the seventh consecutive quarter of record revenue, the filing said.The increase was mainly due to increased market penetration, particularly Australia, as well as initial financial contributions from early Remplir nerve repair product surgical cases in the US, per the filing.Shares rose past 1% in morning trade Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2601584738","title":"Orthocell Ltd -  Revenue a$3.2 Mln for Quarter Ended 31 December","url":"https://stock-news.laohu8.com/highlight/detail?id=2601584738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601584738?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:34","pubTimestamp":1767652456,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y618G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2592928082","title":"Orthocell Sells 100 Units of Nerve Repair Product in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2592928082","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592928082?lang=en_us&edition=fundamental","pubTime":"2025-12-18 10:15","pubTimestamp":1766024133,"startTime":"0","endTime":"0","summary":"Orthocell  said it sold 100 units of its Remplir nerve repair product in the US, according to a Thursday Australian bourse filing.This follows 61 active submissions to US hospital Value Analysis Committees, with 17 approvals secured ahead of schedule and additional approvals anticipated in fiscal 2026, the filing said. The first 4,000 units of Remplir have been shipped from Australia and warehoused in the US.Orthocell's shares fell past 2% in recent trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2592607189","title":"Canaccord Genuity Starts Orthocell at Speculative Buy with AU$1.33 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2592607189","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592607189?lang=en_us&edition=fundamental","pubTime":"2025-12-17 16:41","pubTimestamp":1765960918,"startTime":"0","endTime":"0","summary":"Canaccord Genuity Starts Orthocell at Speculative Buy with AU$1.33 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2591960306","title":"Orthocell Submits Application to the British Standards Institution for Approval for Commercial Distribution of Nerve Repair Product, Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591960306","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591960306?lang=en_us&edition=fundamental","pubTime":"2025-12-15 10:24","pubTimestamp":1765765494,"startTime":"0","endTime":"0","summary":"Orthocell  submitted a regulatory application to the British Standards Institution for approval to commercially distribute its nerve repair product Remplir into the European Union and UK markets, according to a Monday Australian bourse filing.The regulatory approval for the required European Conformity  and UK Conformity Assessed  certifications is expected to be received in the September quarter of 2026.Its shares rose 3% in recent trading on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7067","EC","BK4201","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":63,"code":"91000000","status":"200"}]}}